低危前列腺癌主动监测与根治性治疗的患者报告结局比较
这项多中心前瞻性队列研究纳入德国、奥地利和瑞士2016至2023年6265例低危前列腺癌患者,比较主动监测与神经保留根治性前列腺切除术、非神经保留根治性前列腺切除术或放疗后12个月EPIC-26功能结局。主动监测各功能域稳定,而根治性前列腺切除术组尿控和性功能显著下降且超过最小重要差异阈值,放疗组在刺激/梗阻性排尿、肠道、激素和性功能方面出现临床相关下降。
要点
- 主动监测12个月时所有EPIC-26功能域保持稳定。
- 神经保留根治性前列腺切除术尿控降18分、性功能降35分,超过最小重要差异阈值。
- 放疗后尿控未下降,但刺激/梗阻性排尿、肠道、激素和性功能出现临床相关下降。
核心结论
- 主动监测相比积极治疗能保留尿控和性功能,支持其作为合适候选者的一线策略。
- 尽管有神经保留技术,根治性前列腺切除术和放疗(程度较轻)仍与显著功能损害相关,即使在年轻男性中也是如此。
- 主动监测在观察队列中使用不足。
研究设计与样本
- 多中心前瞻性队列研究,使用德国、奥地利和瑞士的前列腺癌结局研究数据。
- 纳入2016至2023年6265例低危前列腺癌患者。
- 在基线和治疗/入组后12个月使用26项扩展前列腺癌指数综合简表评估患者报告结局。
- 比较平均评分变化与最小重要差异以确定临床显著性。
主要发现
- 475例接受主动监测,4352例接受神经保留根治性前列腺切除术,813例接受非神经保留根治性前列腺切除术,625例接受放疗。
- 12个月时主动监测在所有EPIC-26功能域保持稳定。
- 神经保留根治性前列腺切除术组尿控下降18分、性功能下降35分,超过最小重要差异阈值。
- 非神经保留根治性前列腺切除术组尿控下降26分、性功能下降30分,超过最小重要差异阈值。
- 放疗组尿控未下降,但刺激/梗阻性排尿下降5分、肠道下降7分、激素下降5分、性功能下降12分,为临床相关下降。
关键数值与推荐
- 年龄分层分析显示神经保留根治性前列腺切除术在所有年龄组均出现尿控和性功能的临床显著下降。
- 年轻患者性功能损失最大,70-79岁年龄组尿控损害最明显。
- 主动监测在所有年龄队列中功能结局保持稳定。
临床怎么用
- 对于合适候选的低危前列腺癌患者,主动监测应作为一线策略以保留尿控和性功能。
- 临床决策时应告知患者根治性前列腺切除术和放疗即使采用神经保留技术仍存在显著功能损害风险。
- 在观察队列中主动监测使用不足,需加强推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prospectively evaluate functional patient-reported outcomes (PROs) in patients with low-risk prostate cancer (PCa) managed with active surveillance (AS), nerve-sparing radical prostatectomy (NS-RP), non-NS-RP, or radiotherapy (RT). PATIENTS AND METHODS: This multicentre prospective cohort study used data from the Prostate Cancer Outcomes (PCO) study in Germany, Austria and Switzerland, including 6265 patients with low-risk PCa enrolled between 2016 and 2023. PROs were assessed at baseline and 12 months after treatment/enrolment using the 26-item Expanded Prostate Cancer Index Composite Short Form (EPIC-26), measuring urinary continence, bowel, sexual, hormonal, and irritative/obstructive symptoms. Mean score changes were compared with minimal important differences (MIDs) to determine clinical significance. RESULTS: In all, 475, 4352, 813, and 625 patients received AS, NS-RP, non-NS-RP, and RT, respectively. At 12 months, AS was associated with stable function across all EPIC-26 domains. In contrast, both RP groups experienced significant declines in urinary continence (NS-RP: -18 points; non-NS-RP: -26 points) and sexual function (NS-RP: -35 points; non-NS-RP: -30 points), exceeding MID thresholds. Urinary continence did not decline after RT but clinically relevant declines occurred in irritative/obstructive urinary (-5 points), bowel (-7 points), hormonal (-5 points), and sexual function (-12 points). Age-stratified analysis showed clinically significant declines in urinary and sexual function after NS-RP across all age groups, with the greatest loss in sexual function among younger patients and the most pronounced continence impairment in the 70-79 years age group. In contrast, functional outcomes under AS remained stable in all age cohorts. CONCLUSION: Active surveillance is underutilised in the observed cohort. Prospective PCO data demonstrates that AS preserves urinary continence and sexual function compared to active treatment, supporting its role as the first-line strategy for suitable candidates. Despite advancements including NS techniques, RP, and to a lesser extent RT, remain associated with substantial functional impairment even in younger men.
引用
- Al-Nader M, Kesch C, Mahmoud O, et al. Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer. BJU Int. 2026. PMID: 41698790. doi:10.1111/bju.70167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。